Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — H1 2020 Earnings Presentation
14 slides from Zealand Pharma A/s's earnings presentation, Aug 14, 2020
Slide 1: Interim report for the first half of 2020
Interim report for the first half of 2020 Zealand Pharma August 13, 2020
Slide 2: Disclaimer and forward-looking statements
This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this pre
Slide 3: Business highlights for H1 2020 and subsequent events
Business highlights for H1 2020 and subsequent events •Announced FDA filing and acceptance of New Drug Application (NDA) for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia •Completed enrollment in the first Phase 3 trial of dasiglucagon for the treatment of congenital hype
Slide 4: COVID-19 response: safety, research, clinical trials and engagement
Safety of our people Taking precautions to keep our employees, patients and business and clinical partners safe Research activities Adjusting the way we work so that laboratory-based research and development activities have continued with minimal interruption Clinical trials Continuing enrollment in
Slide 5: Income statement
Income statement DKK thousand H1 2019 Revenue 233,432 19,918 Gross Margin 205,406 19,734 Research and Development Expense -291,658 -256,910 Sales and Marketing Expense 74,853 0 Administrative Expense -70,665 -35,191 Operating result 230,912 272,072 Net financial items -9,003 4,794 Result before tax
Slide 6: Net operating expenses and cash position
Net Operating Expenses DKK 437.2 million / USD 65.7 million Cash position DKK 1.65 billion / USD 247.2 million DKKm 700 600 500 400 300 200 100 DKKm 1.800 1.600 1.400 1.200 1.000 800 600 400 200 0 20162017201820191H 2020 R&D expenseG&A expenseSales and Marketing expense 0 20162017201820191H 2020 Cas
Slide 7: 2020 financial guidance
2020 financial guidance There is no change to the operating expense guidance announced on May 14, 2020, which reflected an increase in guidance for 2020 net operating expenses from DKK 790-810 million due to the completion of the asset purchase agreement for Valeritas, which closed on April 2, 2020.
Slide 8: R&D Pipeline
R&D Pipeline Product Candidate Partner Indication Pre-clinicalPhase 1Phase 2Phase 3Registration Upcoming Milestones Dasiglucagon HypoPal® Rescue Pen Dasiglucagon S.C. Continuous Infusion Dasiglucagon Dual-hormone Pump Dasiglucagon Adjustable Mini-Dose Severe hypoglycemia Congenital hyperinsulinism D
Slide 9: Dasiglucagon via different product modalities
We are pursuing multiple opportunities to improve patients’ lives with dasiglucagon via different product modalities Dasiglucagon Novel stable glucagon analog Fast onset-of-action Unique stability in liquid formulation Suitable for multiple indications HypoPal® rescue pen for severe hypoglycemia NDA
Slide 10: Severe hypoglycemia and dasiglucagon HypoPal rescue pen
Severe hypoglycemia is one of the most feared complications for diabetes patients on insulin therapy1 Our Solution Dasiglucagon HypoPal® – a stable glucagon analog for fast rescue treatment of severe hypoglycemia For illustration only Fast onset of action: Three Phase 3 trials met all primary and ke
Slide 11: Congenital hyperinsulinism and dasiglucagon Phase 3 trials
Congenital hyperinsulinism (CHI) is an ultra-rare and devastating congenital disorder in newborns Our Solution A potential first-in-class glucagon analog for short-and long-term glycemic stabilization of children with CHIFor illustration only Phase 3 trials in children with CHI: First Phase 3 with 3
Slide 12: Short bowel syndrome and glepaglutide
Short bowel syndrome is a chronic and debilitating disease affecting up to 40,000 people in the U.S. and Europe1,2 Rare and severe disease that impairs intestinal absorption, diarrhea and metabolic complications3 Life-long dependency Complex parenteral support to survive and risk of life-threatening
Slide 13: 2020 is a significant year for Zealand: 5x25 commercialized products by 2025
2020 is a significant year of Zealand 5x25 5 commercialized products by 2025 2020 Commercial foundation established 4 Late stage assets and robust early pipeline 2 License partnerships 313 Employees Fully integrated biotech with U.S. commercial presence Commercial platform in place to launch metabol
Slide 14: Zealand Pharma
ZEALAND PHARNA